|
Market Closed -
London S.E.
00:35:29 07/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 13,930.00 GBX | -0.80% |
|
+6.73% | +1.02% |
| 08:01pm | Sharp price movements on the Stockholm Stock Exchange at lunchtime | FW |
| 05:11pm | FTSE 100 slumps as global stocks sell off | AN |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 288,751 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | 0.33% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 309,583 | 302,399 | 293,379 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -0.52% | -2.32% | -2.98% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 24.5x | 20.9x | 18.5x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 5.31x | 4.64x | 3.99x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.5x | 1.2x | 1.4x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.56x | 4.29x | 4.04x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.89x | 4.49x | 4.1x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 13.8x | 12.4x | 10.9x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 14.6x | 13x | 11.5x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 33.9x | 24.1x | 20x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 2.95% | 4.15% | 4.99% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.328 | 3.541 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.79% | 1.9% | 1.96% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.611 | 8.911 | 10.09 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.7% | 39.7% | 36.2% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,331 | 67,370 | 71,478 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,477 | 24,432 | 27,021 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,258 | 23,264 | 25,559 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,722 | 13,592 | 15,310 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 20,832 | 13,649 | 4,629 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 186.17 | 186.17 | 186.17 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 10/2/22 | 9/2/23 | 8/2/24 | 6/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 24.85x | 4.96x | 13.98x | 1.76% | 293B | |
| 39.94x | 13.51x | 30.01x | 0.5% | 1,216B | |
| 39.86x | 6.69x | 18.83x | 1.96% | 656B | |
| 37.08x | 8.43x | 17.39x | 2.4% | 509B | |
| 21.12x | 5.13x | 12.77x | 2.56% | 384B | |
| 97.32x | 5.95x | 25.36x | 2.32% | 362B | |
| 23.5x | 6.02x | 14.53x | 2.65% | 311B | |
| 28.41x | 7.33x | 12.69x | 2.19% | 249B | |
| -40.11x | 7.32x | 45.99x | 1.97% | 208B | |
| 11.88x | 4.33x | 8.89x | 4.21% | 180B | |
| Average | 28.38x | 6.97x | 20.04x | 2.25% | 436.74B | |
| Weighted average by Cap. | 34.89x | 8.40x | 21.68x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
